NYSE: QGENQiagen Nv Stock
$47.08+0.26 (+0.56%)
Updated Dec 4, 2025
QGEN Price
$47.08
Fair Value Price
N/A
Market Cap
$10.25B
52 Week Low
$37.63
52 Week High
$51.88
P/E
25.31x
P/B
2.81x
P/S
4.68x
PEG
1.69x
Dividend Yield
N/A
Revenue
$2.07B
Earnings
$405.37M
Gross Margin
63.1%
Operating Margin
26.14%
Profit Margin
19.6%
Debt to Equity
0.8
Operating Cash Flow
$658M
Beta
0.63
Next Earnings
Feb 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
QGEN Overview
Qiagen N.V. offers molecular diagnostics, applied testing, academic and pharmaceutical research. Specific offerings include nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies. It also offers secondary sample technology consumable (kits and components for purification of nucleic acids, instruments for nucleic acid purification, and accessories). Qiagen N.V was founded in 1986 and is headquartered in Venlo, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QGEN's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
QGEN
Ranked#9 of 48
Ranked#9 of 48
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.56 | A | |
| $717.47 | B | |
| $227.13 | B |
Be the first to know about important QGEN news, forecast changes, insider trades & much more!
QGEN News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QGEN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QGEN ($47.08) is trading above its intrinsic value of $21.29, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
QGEN is good value based on its earnings relative to its share price (25.31x), compared to the US market average (46.53x)
P/E vs Market Valuation
QGEN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more QGEN due diligence checks available for Premium users.
Valuation
QGEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
25.31x
Industry
22.02x
Market
46.53x
QGEN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
QGEN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
QGEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.81x
Industry
4.48x
QGEN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QGEN price to earnings growth (PEG)
For valuing profitable companies with growth potential
QGEN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
QGEN's financial health
Profit margin
Revenue
$532.6M
Net Income
$130.0M
Profit Margin
24.4%
QGEN's Earnings (EBIT) of $541.21M... subscribe to Premium to read more.
Interest Coverage Financials
QGEN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.6B
Liabilities
$2.9B
Debt to equity
0.8
QGEN's short-term assets ($2.53B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QGEN's short-term assets ($2.53B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QGEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QGEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$165.0M
Investing
-$156.9M
Financing
$614.1M
QGEN's operating cash flow ($657.70M)... subscribe to Premium to read more.
Debt Coverage Financials
QGEN vs Diagnostic & Research Stocks
Qiagen Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.